Athlete’s foot- Epidemiology Forecast to 2030

Athlete’s foot- Epidemiology Forecast to 2030

  • May 2020 •
  • 100 pages •
  • Report ID: 5897609 •
  • Format: PDF
‘Athlete’s foot - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Athlete’s foot epidemiology in the United States.

Athlete’s foot Understanding
Athlete’s foot, also known as Tinea pedis, is a cutaneous fungal infection caused by a dermatophyte infection. It is characterized by itching, flaking, and fissuring of the skin. It may manifest in three ways: the skin between the toes may appear macerated (white) and soggy; the soles of the feet may become dry and scaly; the skin all over the foot may become red, and vesicular eruptions may appear.

Three groups of fungal pathogens, referred to as dermatophytes, have been shown to cause tinea pedis: Trichophyton sp, Epidermophyton sp, and Microsporum sp. The disease manifests as a pruritic, erythematous, scaly eruption on foot and depending on its location, three variants have been described: interdigital type, moccasin type, and vesiculobullous type.

Athlete’s foot Epidemiology Perspective
The Athlete’s foot epidemiology division provides the insights about historical and current patient pool and forecasted trend for the United States. The Athlete’s foot epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in the United States. The Athlete’s foot epidemiology is segmented by Diagnosed incident cases of Athlete’s foot and Incident cases of Athlete’s foot by subtype covering the United States from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Athlete’s foot Detailed Epidemiology Segmentation
The Athlete’s foot epidemiology covered in the report provides historical as well as forecasted epidemiology {Total Diagnosed Incident Cases and Subtype-specific Cases} scenario of Athlete’s foot in the United States from 2017 to 2030.
The Athlete’s foot report also provides the epidemiology trends observed in the United States during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
• The Athlete’s foot report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Athlete’s foot Epidemiology Report and Model provide an overview of the risk factors and global trends of Athlete’s foot in the United States
• The report provides insight about the historical and forecasted patient pool of Athlete’s foot in the United States
• The report helps to recognize the growth opportunities in the United States with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Athlete’s foot
• The report provides the segmentation of the Athlete’s foot epidemiology by Subtype-specific Cases of Athlete’s foot in the United States

Report Highlights
• 11-Year Forecast of Athlete’s foot epidemiology
• United States Coverage
• Total Incident Cases of Athlete’s foot
• Incident Cases according to segmentation: Subtype-specific Incidence
• Diagnosed cases of Athlete’s foot
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the United States with respect to the patient population pertaining to Athlete’s foot?
• What are the key findings pertaining to the Athlete’s foot epidemiology in the United States?
• What would be the total number of patients of Athlete’s foot in the United States during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in the United States during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the Athlete’s foot?
• What are the current available treatments of Athlete’s foot?

Reasons to buy
The Athlete’s foot Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Athlete’s foot market
• Quantify patient populations in the global Athlete’s foot market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Athlete’s foot therapeutics in each of the markets covered
• Understand the magnitude of Athlete’s foot population by its severity
• The Athlete’s foot epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Athlete’s foot Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden

• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
Study Period: 2017–2030
IQWiG (Institute for Quality and Efficiency in Health Care) suggests that Athlete’s foot is very common affecting 3 to 15% of the population. Similarly, a study published by Nigam et al. highlights that about 10% of the total population may be affected by dermatophyte infections of the toe clefts. It is mostly attributed to wearing of occlusive shoes for long periods.
The study by Muhannad Al Hasan et al. points towards an important fact that Tinea pedis is estimated to be the second most common skin disease in the United States, behind acne, and up to 15% of the population may manifest the disease.